{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:26:05Z","timestamp":1787826365947,"version":"build-2784847793"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Previous research has proposed a luteinizing hormone (LH) threshold and ceiling level, below which oestradiol production is not adequate and above which LH may be detrimental to follicular development. This therapeutic LH window was mainly supported by clinical research in anovulatory patients but observations in normogonadotropic women were controversial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      A literature narrative review from 1985 through 2025. Studies evaluated included i) preclinical studies using\n                      <jats:italic>in vivo<\/jats:italic>\n                      superovulation models in rodents and ii) clinical studies in normogonadotropic IVF patients undergoing OS with recombinant FSH (r-FSH) supplemented with r-LH, urinary human chorionic gonadotropin (u-hCG) or r-hCG or with human menopausal gonadotropin (hMG).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In rodents, small amounts of LH\/hCG support FSH-induced multiple follicular development in absence of endogenous gonadotropins, while too high LH\/hCG exposure consistently induced follicular atresia. In women treatment with too high doses of GnRH agonist or antagonist resulted in undetectable serum LH (well below 1 IU\/L), impaired follicular growth, low rises of serum oestradiol, early miscarriage and reduced chance of pregnancy. Too profound suppression was observed in patients treated with a long GnRH agonist protocol, but the incidence depends on the specific agonist, dose and route of administration. Most women treated with the GnRH antagonist protocol, without other pituitary-suppression, remain within the therapeutic LH window (endogenous LH 1\u201310 IU\/L) during the whole stimulation period. In contrast, too much LH\/hCG supplementation can compromise clinical outcome, as confirmed in IVF patients treated with r-FSH and a potent r-hCG in a long GnRH agonist protocol. This r-hCG in daily doses of 1 \u00b5g or more inhibited the growth of medium-sized follicles which phenomenon has previously also observed in IVF patients treated with u-hCG and in PCOS patients treated with r-LH during ovulation induction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Whether commercial combination gonadotropins have inhibitory effects on multiple follicular development is difficult to judge and may depend on the protocol, dose of FSH, dose of LH\/hCG, number of treatment days and the potency of the specific LH\/hCG preparation. It is concluded that normogonadotropic IVF patients undergoing OS have a clearly defined therapeutic LH window below and above which clinical outcome is compromised.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1835446","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:15:50Z","timestamp":1786972550000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Re-assessment of the therapeutic LH window in normogonadotropic IVF patients"],"prefix":"10.3389","volume":"17","author":[{"given":"Bernadette","family":"Mannaerts","sequence":"first","affiliation":[{"name":"Mannaerts Consultancy","place":["Heesch, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin M.","family":"Howles","sequence":"additional","affiliation":[{"name":"ARIES Consulting Sarl","place":["Geneva, Switzerland"]},{"name":"Deanery of Biomedical Sciences, University of Edinburgh","place":["Edinburgh, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus Yding","family":"Andersen","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen","place":["Copenhagen, Denmark"]},{"name":"The Fertility Clinic, Copenhagen University Hospital Herlev","place":["Herlev, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7827-12-95","article-title":"A review of luteinising hormone and human chorionic gonadotropin when used in assisted reproductive technology","volume":"12","author":"Ezcurra","year":"2014","journal-title":"Reprod Biol Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/15.11.2258","article-title":"The role of LH in ovarian stimulation exogenous LH: let\u2019s design the future","volume":"15","author":"L\u00e9vy","year":"2000","journal-title":"Hum Reprod"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/OXFORDJOURNALS.HUMREP.A138685","article-title":"Recombinant human follicle-stimulating hormone and ovarian response in gonadotrophin-deficient women","volume":"9","author":"Schoot","year":"1994","journal-title":"Hum Reprod"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/0303-7207(94)90278-X","article-title":"Follicular oestrogen synthesis: the \u201ctwo-cell, two-gonadotrophin\u201d model revisited","volume":"100","author":"Millier","year":"1994","journal-title":"Mol Cell Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2024.104782","article-title":"Does hCG\/LH supplementation during ovarian stimulation improve clinical outcome? An evaluation of 30 years clinical research","volume":"50","author":"Mannaerts","year":"2025","journal-title":"Reprod BioMed Online"},{"key":"B6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1095\/BIOLREPROD51.1.72","article-title":"Folliculogenesis in hypophysectomized rats after treatment with recombinant human follicle-stimulating hormone","volume":"51","author":"Mannaerts","year":"1994","journal-title":"Biol Reprod"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020569508927","article-title":"Requirements for human chorionic gonadotropin and recombinant human luteinizing hormone for follicular development and maturation","volume":"16","author":"Andersen","year":"1999","journal-title":"J Assist Reprod Genet"},{"key":"B8","first-page":"568","article-title":"The effect of recombinant hCG on FSH-induced ovarian stimulation in rats depends on the FSH dose and can be detrimental at high concentrations","volume-title":"Hum Reprod","author":"Schoeller","year":"2022"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/HUMREP\/15.7.1490","article-title":"Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial","volume":"15","author":"Borm","year":"2000","journal-title":"Hum Reprod"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/HUMREP\/16.4.644","article-title":"Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation","volume":"16","year":"2001","journal-title":"Hum Reprod"},{"key":"B11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0015-0282(00)01638-1","article-title":"Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation","volume":"75","author":"Fluker","year":"2001","journal-title":"Fertil Steril"},{"key":"B12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.xfre.2023.02.009","article-title":"Ganirelix and the prevention of premature luteinizing hormone surges","volume":"4","author":"Mannaerts","year":"2023","journal-title":"F S Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1477-7827-11-90","article-title":"Clinical impact of LH rises prior to and during ganirelix treatment started on day 5 or on day 6 of ovarian stimulation","volume":"11","author":"Frattarelli","year":"2013","journal-title":"Reprod Biol Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(01)01973-2","article-title":"Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a prospective randomized study","volume":"76","author":"Westergaard","year":"2001","journal-title":"Fertil Steril"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/HUMREP\/16.8.1636","article-title":"Suppression of LH during ovarian stimulation: analysing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH","volume":"16","author":"Balasch","year":"2001","journal-title":"Hum Reprod"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/HUMREP\/17.8.2016","article-title":"Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation","volume":"17","author":"Humaidan","year":"2002","journal-title":"Hum Reprod"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(02)03157-6","article-title":"The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation","volume":"77","author":"Shoham","year":"2002","journal-title":"Fertil Steril"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/S10815-005-5998-8","article-title":"Differences in serum LH and FSH levels using depot or daily GnRH agonists in controlled ovarian stimulation: influence on ovarian response and outcome of ART","volume":"22","author":"Sonntag","year":"2005","journal-title":"J Assist Reprod Genet"},{"key":"B19","article-title":"Ovarian response and pregnancy outcome related to midfollicular LH levels in down-regulated women undergoing assisted reproduction","volume":"49","author":"Ferrari","year":"2004","journal-title":"J Reprod Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2011.06.015","article-title":"No association between endogenous LH levels and ongoing pregnancy rates in a large randomized trial of corifollitropin alfa and rFSH using a GnRH antagonist protocol: part I","volume":"23","author":"Doody","year":"2011","journal-title":"Reprod BioMed Online"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2011.06.016","article-title":"No association between endogenous LH levels and ongoing pregnancy rates in a combined analysis of 1764 patients treated with a rFSH\/GnRH antagonist protocol: part II","volume":"23","author":"Griesinger","year":"2011","journal-title":"Reprod BioMed Online"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s43032-021-00608-0","article-title":"The effect of luteinising hormone suppression in in vitro fertilisation antagonist cycles","volume":"28","author":"Goh","year":"2021","journal-title":"Reprod Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/S13048-023-01110-8","article-title":"LH level on ovulation trigger day has a different impact on the outcomes of agonist and antagonist regimens during in vitro fertilization","volume":"16","author":"Luo","year":"2023","journal-title":"J Ovarian Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/13.11.3023","article-title":"A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone","volume":"13","year":"1998","journal-title":"Hum Reprod"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/HUMREP\/DEI243","article-title":"Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist or in natural cycles","volume":"20","author":"Simon","year":"2005","journal-title":"Hum Reprod"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/OXFORDJOURNALS.HUMREP.A138480","article-title":"Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis","volume":"9","author":"Hillier","year":"1994","journal-title":"Hum Reprod"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/OXFORDJOURNALS.HUMREP.A137615","article-title":"Regulation of aromatase activity in FSH-primed rat granulosa cells in vitro by follicle-stimulating hormone and various amounts of human chorionic gonadotrophin","volume":"7","author":"Overes","year":"1992","journal-title":"Hum Reprod"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.74.4.1548349","article-title":"Hormonal regulation of the growth and steroidogenic function of human granulosa cells","volume":"74","author":"Yong","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)90395-8","article-title":"Effect of high tonic levels of luteinising hormone on outcome of in vitro fertilization","volume":"328","author":"Howles","year":"1986","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)92765-A","article-title":"Hypersecretion of luteinising hormone, infertility, and miscarriage","volume":"336","author":"Regan","year":"1990","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/HUMREP\/DEG066","article-title":"Clinical evidence for an LH \u201cceiling\u201d effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation","volume":"18","author":"Loumaye","year":"2003","journal-title":"Hum Reprod"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/HUMREP\/DEH682","article-title":"Does the addition of recombinant LH in WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose-finding study","volume":"20","author":"Hugues","year":"2005","journal-title":"Hum Reprod"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dead156","article-title":"Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome\u2020","volume":"38","author":"Teede","year":"2023","journal-title":"Hum Reprod"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/HUMREP\/DEL284","article-title":"Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial","volume":"21","author":"Nyboe Andersen","year":"2006","journal-title":"Hum Reprod"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/HUMREP\/DEM221","article-title":"Influence of ovarian stimulation with HP-hMG or recombinant FSH on embryo quality parameters in patients undergoing IVF","volume":"22","author":"Ziebe","year":"2007","journal-title":"Hum Reprod"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2011.12.016","article-title":"A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer Menopur in GnRH Antagonist Cycles with Single Embryo Transfer (MEGASET) Trial Group","volume":"97","author":"Devroey","year":"2012","journal-title":"Fert Steril"},{"key":"B37","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3109\/09513590.2012.705379","article-title":"Live-birth rates after HP-hMG stimulation in the long GnRH agonist protocol: association with mid-follicular hCG and progesterone concentrations, but not with LH concentrations","volume":"29","author":"Arce","year":"2013","journal-title":"Gynecol Endocrinol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/HUMREP\/DES256","article-title":"A randomized controlled dose-response pilot study of addition of hCG to recombinant FSH during controlled ovarian stimulation for in vitro fertilization","volume":"27","author":"Thuesen","year":"2012","journal-title":"Hum Reprod"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/HUMREP\/DEAC061","article-title":"A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol","volume":"37","author":"Fern\u00e1ndez S\u00e1nchez","year":"2022","journal-title":"Hum Reprod"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deaa043","article-title":"Two waves of transcriptomic changes in periovulatory human granulosa cells","volume":"35","author":"Poulsen","year":"2020","journal-title":"Hum Reprod"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2026.1791342","article-title":"The ovulation trigger method changes gonadotropin concentrations and gonadotropin receptor expression during final oocyte maturation in women","volume":"17","author":"Poulsen","year":"","journal-title":"Front Endocrinol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13037","article-title":"First-in-human trial assessing the pharmacokinetic-pharmacodynamic profile of a novel recombinant human chorionic gonadotropin in healthy women and men of reproductive age","volume":"14","author":"Broks\u00f8 Kyhl","year":"2021","journal-title":"Clin Transl Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/s1472-6483(10)","article-title":"Pharmacokinetics and pharmacodynamics of recombinant human chorionic gonadotrophin in healthy male and female volunteers","volume":"4","author":"Trinchard-Lugan","year":"2002","journal-title":"Reprod BioMed Online"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/13.9.2386","article-title":"Gonadotrophin-releasing hormone agonist dose-dependency of pituitary desensitization during controlled ovarian hyperstimulation in IVF","volume":"13","author":"Janssen-Janssens","year":"1998","journal-title":"Hum Reprod"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3109\/09513590.2012.665103","article-title":"A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy rates","volume":"28","author":"Qiao","year":"2012","journal-title":"Gynecol Endocrinol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/15.11.2333","article-title":"Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study","volume":"15","author":"Janssens","year":"2000","journal-title":"Hum Reprod"},{"key":"B47","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3275\/8657","article-title":"Efficacy of different gonadotropin combinations to support ovulation induction in WHO type I anovulation infertility: clinical evidences of human recombinant FSH\/human recombinant LH in a 2:1 ratio and highly purified human menopausal gonadotropin stimulation protocols","volume":"35","author":"Carone","year":"2012","journal-title":"J Endocrinol Invest"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2012.02.028","article-title":"Pretreatment with estrogen does not affect IVF-ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomized trial","volume":"97","author":"C\u00e9drin-Durnerin","year":"2012","journal-title":"Fertil Steril"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1515\/med-2022-0594","article-title":"Estradiol pretreatment in GnRH antagonist protocol for IVF\/ICSI treatment","volume":"17","author":"Zhu","year":"2022","journal-title":"Open Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2008.01.007","article-title":"Oral contraceptive pretreatment in women undergoing controlled ovarian stimulation in ganirelix acetate cycles may, for a subset of patients, be associated with low serum luteinizing hormone levels, reduced ovarian response to gonadotropins, and early pregnancy loss","volume":"91","author":"Meldrum","year":"2009","journal-title":"Fertil Steril"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3598","article-title":"Evidence of GnRH antagonist escape in obese women","volume":"99","author":"Roth","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/s0950-3552(97)80036-3","article-title":"Role of androgens in follicle maturation and atresia","volume":"11","author":"Hillier","year":"1997","journal-title":"Baillieres Clin Obstet Gynaecol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-0760(97)80017-9","article-title":"Differential regulation of aromatase and androgen receptor in granulosa cells","volume":"61","author":"Tetsuka","year":"1997","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1427","article-title":"LH-receptor gene expression in human granulosa and cumulus cells from antral and preovulatory follicles","volume":"97","author":"Jeppesen","year":"2012","journal-title":"J Clin Endorinol Metab"},{"key":"B55","doi-asserted-by":"publisher","first-page":"105154","DOI":"10.1016\/j.rbmo.2025.105154","article-title":"Disentangling the current role of LH activity in assisted reproduction: from biology to patient personalization","volume":"52","author":"Bellver","year":"2025","journal-title":"Reprod BioMed Online"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2015.06.002","article-title":"Randomized trial comparing luteinizing hormone supplementation timing strategies in older women undergoing ovarian stimulation","volume":"31","author":"Behre","year":"2015","journal-title":"Reprod BioMed Online"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dew360","article-title":"Efficacy and safety of follitropin alfa \/ lutropin alfa in ART: a randomized controlled trial in poor ovarian responders","volume":"31","author":"Humaidan","year":"2017","journal-title":"Hum Reprod"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1835446\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:16:03Z","timestamp":1787825763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1835446\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":57,"alternative-id":["10.3389\/fendo.2026.1835446"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1835446","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"article-number":"1835446"}}